2013, Number 6
<< Back Next >>
Rev Med Inst Mex Seguro Soc 2013; 51 (6)
Use of collagen-polyvinylpirrolidone in the treatment of Parry-Romberg syndrome
Hernández-Vega GA, Ruiz-Eng R, Montiel-Jarquín Á, Gómez-Conde E, López-Colombo A, Pérez-Aguilar A, Bejarano-Huertas R
Language: Spanish
References: 12
Page: 692-695
PDF size: 184.31 Kb.
ABSTRACT
Background: Parry-Romberg syndrome is characterized by the presence
of progressive hemifacial atrophy that affects the growth and
development of structures on one side of the face. Our objective was to
introduce collagen-polyvinylpirrolidone as a new therapeutic option for
Parry-Romberg syndrome in two clinical cases.
Clinical cases: two women, aging 56 and 28 years old, with facial
hypocrhomic lesions, and right and left fronto-malar sunken area respectively,
treated with topic steroids + penicilamina, fat grafts and silicone
implants without improvement. We used collagen-polyvinylpirrolidone
and they showed improvement: after six months there were not clinical
or esthetical complications.
Conclusions: collagen-polivinilpirrolidone could be a new therapeutic
option for Parry-Romberg syndrome with good clinical and esthetical
results. It is easy to apply and it has few side effects and without complications.
REFERENCES
Waters MF, Bhidayasiri R, Shields WD. Favorable longitudinal outcome in a patient with Parry-Romberg syndrome. Acta Neurol Scand. 2005:112(3): 192-3.
Budrewicz S, Koszewicz M, Koziorowska-Gawron E, Szewczyk P, Podemski R, Slotwisńki K. Parry-Romberg syndrome: clinical, elctrophysiological and neuroimaging correlations. Neurol Sci. 2012;33(2):423-7.
Okumura A, Ikuta T, Tsuji T, Kato T, Fukatsu H, Nagagawa S, et al. Parry-Romberg syndrome with a clinically silent white matter lesion. AJNR Am J Neuroradiol. 2006;27(8):1729-31.
Castañeda-Reyna MA, Galarza-Manyari C. Síndrome de Parry-Romberg asociado a epilepsia refractaria, atrofi a de la duramadre y leucoencefalopatía quística cerebral. Rev Neurol. 2003;37(10):941-5.
Gonul M, Dogan B, Izci Y, Varol G. Parry-Romberg syndrome in association with anti-dsDNA antibodies: a case report. J Eur Acad Dermatol Venereol. 2005;19(6):740-2.
Ruffatti A, Peserico A, Rondinone R, Calligaro A, Del-Ross T, Ghirardello A, et al. Prevalence and characteristics of ant-single-stranded DNA antibodies in localized scleroderma. Comparison with systemic lupus erythematosus. Arch Dermatol. 1991;12 7(8):1180-3.
Honda-Fujimura SA, Galván-Esquivel V, Montes de Oca F, Ysita-Morales A. Calcitriol oral en el tratamiento de la esclerodermia localizada. Educ Invest Clin. 2000;1(2):92-6.
Berenguer B, Gallo H, Rodríguez-Urcelay P, Marín- Guztke M, González-Meli B, Enríquez-de Salamanca J. Trasplante libre de grasa para tratamiento de la enfermedad de Parry-Romberg infantil. Cir Pediatr. 2005;18(1):49-51.
Furuzawa-Carballeda CZ, García-Aranda RL, Furuzawa- Carballeda J. Estudio piloto sobre la efi cacia del uso de la colágena-polivinilpirrolidona (clg-PVP) en la regeneración ósea en cirugía endodóncica. Rev Odontol Mex. 2005;9(4):191-6.
Furuzaawa-Carballeda J, Rojas E, Valverde M, Castillo I, Díaz de León L, Krötzsch E. Cellular and humoral responses to collagen-polyvinylpyrrolidone administered during short and long periods in humans. Can J Physiol Pharmacol. 2003;81(11): 1029-35.
Furuzawa-Carballeda J, Krötzsch E, Barilé-Fabris L, Alcalá M, Espinosa-Morales R. Subcutaneous administration of collagen-polyvinylpyrrolidone down regulates IL-1β, TNF-α, TGF-β1, ELAM-1 and VCAM- 1 expression in scleroderma skin lesions. Clin Exp Dermatol. 2005;30(1):83-6.
Sikes PJ. Application of microvascular surgery to plastic surgery. J R Soc Med. 1980;73(1):55-9
Full text